New research results for people with chronic kidney disease and acute kidney injur! 🎉
Dr Bryan Conway and his team have identified a group of cells in the kidney that emerge during chronic kidney disease, or after acute kidney injury, that lead to a loss of kidney function.
Read the full story here: https://t.co/dAJA3t6PJ9
New paper alert - Congrats to our @EdinburghKidney team for this great study identifying how specific subset of tubular cells drive disease progression
https://t.co/rCWt2iKYks
📢📢📢 New paper alert from the @EdinburghKidney
Urinary senescene biomarker identified
Urinary Clusterin is a Biomarker of Renal Epithelial Senescence and Predicts Human Kidney Disease Progression - Kidney International Reports https://t.co/K445PK9Cry
"The QUOD biobank is an incredibly powerful resource and has allowed me to access samples that simply would not be available from anywhere else."
@davidbaird86, @EdinburghUni
To win £5000 of QUOD samples:
https://t.co/K01oGlA5NF
@LLTGL@ESOTtransplant
Our session on how QUOD is supporting Higher education, chaired by Dr Luke A. Yates, showcasing 3 researchers, Rebecca Vaughan, David Baird, and Ioannis Michelakis, using #QUODbiobank samples.
@NHSBT@NDSurgicalSci@UniofOxford
Interested in rare models and biological research beyond the standard? Looking to diversify your research?
Join us in Edinburgh to explore how unconventional models are becoming engines for biomedical research
https://t.co/DIRjRS4jIH
🐿️🦌🐒🦍🐀💃
There are days in life that shake you.
I’m shattered 💔 to share that I just found out that the US Government terminated my 2024 NIH Director’s Early Independence Award (~$2 million), threatening my long-promised assistant professor job at @Columbia & academic career... 1/🧵
Cardiovascular 🫀and renal 🫘 effects of apelin 🍏🏨 in chronic kidney disease: a randomised 🎲, double-blind 🕶️🕶️, placebo-controlled 💊, crossover 🔀 study…
Congrats to @fichapman86 from @EdinburghKidney on this new paper in @NatureComms!
https://t.co/eucDHzdVng
⬇️⬇️⬇️
In newly published results, Dr Fiona Chapman, Professor Neeraj Dhaun and the team from the University of Edinburgh conducted the first clinical trial looking at the effects of apelin in patients with chronic kidney disease (CKD).
CKD is a growing public health concern, with around 7.2 million people currently living with the disease.
Read the full story and what these promising results will mean for the future of patients living with CKD.
https://t.co/6KAZN92Gni
Dr Ben Warner discusses multimorbidity, also known as multiple long-term conditions, with Professor Frances Mair. They discuss the burden of treatment and health inequalities for patients.
Link: https://t.co/0NTvavfoDx @FrancesMair@benedictwarner
If you are going to be new to renal training this year we would love to see you at the annual renal crash course in July! 🌟
Covering top tips for the first few months of the job and a chance to meet new colleagues, booking is now open here-
https://t.co/vU3Lc407El
New study with @EdinburghBean @EdinClinTox @EdinburghKidney 👉Choroidal and retinal thinning in chronic kidney disease independently associate with eGFR decline and are modifiable with treatment | Nature Communications https://t.co/NerB5x1Urx
Join us! 👉 @TheBHF PhD programme @EdinburghUni & work with amazing research teams in @EdinUniCVS deadline 15 Jan; start September 2024 🫶 https://t.co/ZI6D3PqNZ4